Le Lézard
Classified in: Health
Subject: TRI

APTtm Formulation Combats Multi-Drug Resistant Candida auris: An Emerging Global Healthcare Threat


ROCKWALL, Texas and INDIANAPOLIS, Feb. 25, 2021 /PRNewswire-PRWeb/ -- Advanced Penetration Technology, LLC, (APT) a Texas- and Indiana-based company specializing in innovative healthcare solutions for physicians and patients utilizing our proprietary APTtm formulations, has received compelling preclinical in vitro and in vivo data against susceptible and resistant Candida auris isolates provided by the CDC. This data provides first time evidence that treatment with the APTtm based antifungal topical formulations can "decolonize" Candida auris. The results indicate that these formulations may have utility to control and prevent the ongoing global spread of this deadly multi-drug resistant fungus.

Candida auris can be fatal. There is up to a 55% mortality rate when C. auris enters the patients' bloodstream. Current treatment protocols, typically involving chlorhexidine baths and intravenous antifungal drugs, have not proven effective in controlling this global spread of C. auris fungus. These recent studies conducted at Case Western Reserve University, including highly resistant strains of C. auris provided by the Centers for Disease Control (CDC), have demonstrated the APTtm based antifungal formulations are highly effective in killing the most resistant strains of this deadly fungus on skin surfaces. The APTtm based antifungal topical formulations are the only known and effective solution to remove C. auris from the skin of patients and healthcare workers. Given these study results, it is believed that this topical "decolonization" application will become the standard of care to stop and control this multi-drug resistant fungal infection across global healthcare systems.

The company is working with world renowned specialists and fungal disease experts, most notably, Dr. Mahmoud Ghannoum, Case Western Reserve University, Cleveland, Ohio. The company is in ongoing discussions with the CDC concerning the immediate impact of the APTtm antifungal formulations will have in controlling this emerging global healthcare threat. A peer reviewed manuscript has been published documenting the effective decolonization application of the APTtm antifungal formulations: https://pubmed.ncbi.nlm.nih.gov/33558297/

Dr. Mahmoud Ghannoum said, "Using a C.auris decolonization model we were able to demonstrate that the treatment with the APTtm formulations were effective in decolonizing the skin of this multi-drug resistant fungi. These findings suggest that these topical formulations may provide a safe and easy method to decolonize the skin of both healthcare workers and patients, thereby interrupting skin colonization by the dangerous pathogen, Candida auris".

"The patent pending, proprietary APTtm platform continues to demonstrate dramatic improvements in the efficacy of existing topical medications. In this case, the APTtm formulation combined with either a 1% Clotrimazole (API) or a 1 % Terbinafine (API) demonstrates to be the most effective topical formulations to remove C. auris from the skin of patients and healthcare workers. The APTtm formulation's unique dual-actions of biophysical and biochemical destruction of Candida auris and other fungal pathogens will change the trajectory of therapeutic discussions, globally," states Dr. Brian J. Huber, CEO/President of PFTH, LLC the parent company of APT, LLC.

Current prevention protocols focus on cleansing the patient with a chlorhexidine bath/solution, which does not effectively manage the C. auris organism and the person to person spread. Environmental decontamination is a dramatic step. Entire hospital rooms are dismantled and cleaned to attempt removal of the C. auris organisms. Once the C. auris fungus accesses the patients' blood stream (via catheters, IV lines, ports, airways) there is a 55 % chance these patients will die within 30-90 days.

According to infectious disease specialists and the CDC, the key point of focus is (decolonizing) removing the C. auris fungus from the skin of patients and healthcare workers. Only by removing/mitigating the person to person spread and subsequently, the environmental contamination process, will the spread of this pathogen be stopped. The APTtm based antifungal formulations used for skin decolonization protocols are a true prevention strategy for global control of C. auris.

About Advanced Penetration Technology, LLC: Advanced Penetration Technology, LLC, is a Texas and Indiana-based pharmaceutical IP company that has created new solutions for areas of patient care using our technology to improve topical therapeutic outcomes. Its products have been used to treat wounds, resistant bacterial infections, resistant fungal infections, burns, acne and other conditions. Founded in in 2016, APT strives to provide access to highly effective care at the primary and home levels on a global scale.

Please visit our site for further information: https://www.aptdeliverysystem.com/

Media Contact

Brian Huber, Patient Focused TeleHealth, LLC, +1 (214) 563-4472, bhuber@patientfocusedtelehealth.com

 

SOURCE Advanced Penetration Technology, LLC


These press releases may also interest you

at 06:35
HEXO Corp ("HEXO" or the "Company") today announced Purchase and Sale Agreements in relation to its first US production facility, through a wholly owned US subsidiary. The ~50,000 sq. ft. facility, located in Northern Colorado, will provide US CPGs...

at 06:30
Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that the Sidney Kimmel Cancer Center ? Jefferson Health (SKCC) has joined Caris'...

at 06:30
The "Artificial Intelligence in Healthcare Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Component, Application, End User, and Geography" report has been added to ResearchAndMarkets.com's offering. Robot Assisted Surgery Segment...

at 06:10
Aurinia Pharmaceuticals Inc. (the "Company") today announced that members of the executive management team will participate in two upcoming investor conferences: RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 10:55...

at 06:05
PharmaEssentia USA Corporation, a subsidiary of Taiwan-based PharmaEssentia Corp. (TPEx: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today...

at 06:05
Metagenomi, a gene editing company, today presented preclinical data on three new CRISPR-associated gene editing systems useful for the development of novel cellular therapies, including T- and NK-cell therapies, at the 24th Annual Meeting of the...



News published on 25 february 2021 at 13:00 and distributed by: